GALT Latest Press Releases

-- May 27, 2026 --

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis Globe Newswire 8:00 AM

-- May 15, 2026 --

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update Globe Newswire 8:00 AM

-- May 11, 2026 --

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology Globe Newswire 8:00 AM

-- April 27, 2026 --

Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm Globe Newswire 9:00 AM

-- March 31, 2026 --

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update Globe Newswire 8:00 AM

-- March 17, 2026 --

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. Globe Newswire 8:00 AM

-- February 26, 2026 --

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET Globe Newswire 4:05 PM

-- January 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT PRNewswire 10:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software